Decoding Big Pharmas R&D Strategy in Oncology

Table of Contents

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

• 4.1 List of Tables

5 Big Pharma' s R&D Position and Strategy in Oncology: A Summary

• 5.1 Bristol-Myers Squibb
• 5.2 GlaxoSmithKline
• 5.3 Hoffmann-La Roche
• 5.4 Novartis
• 5.5 Sanofi-Aventis

6 Last Five Years of Deals and Alliances in Oncology

• 6.1 Bristol Myers Squibb
  • 6.1.1 Discovery and Lead Molecule Improvements
  • 6.1.2 Adding Image Analysis to Support Clinical Trials and Early Diagnosis
  • 6.1.3 Bladder Cancer and Melanoma Registration Filings are Emminent
  • 6.1.4 The Human Kinome and Cell Cycle Inhibitors
  • 6.1.5 Strategic Priorities in Pipeline Development Leads to Divestments
  • 6.1.6 Erbitux Expansion is Set to Challenge Avastin
• 6.2 GlaxoSmithKline
  • 6.2.1 The Biopharmaceutical Strategy at GSK
  • 6.2.2 Out Goes Classes of Small Molecule Inhibitors
  • 6.2.3 Marketing and Manufacturing Collaborations
  • 6.2.4 Patient Selectionfo r GSK' s Targeted Cancer Therapies
  • 6.2.5 GSK Taping Into Knowledge Databases
  • 6.2.6 Increasing the Oral Bioavailability Cytotoxic Oncology Drugs
  • 6.2.7 Oxford University Helps GSK in India
  • 6.2.8 GSK is Set to Improve Medical Imaging
• 6.3 Hoffmann-La Roche
  • 6.3.1 Roche Builds Center of Excellence for RNAi Therapeutics Discovery
  • 6.3.2 A New Delivery Route for Avastin?
  • 6.3.3 Improving Antibody Drugs
  • 6.3.4 Roche Strengthens Presence in Genomics Research Market
  • 6.3.5 Target Validation
  • 6.3.6 Drug Discovery Collaborations
  • 6.3.7 Marketing
  • 6.3.8 Outlicensing
  • 6.3.9 Size Doesn' t Matter: Genentech' s Goal of Aggressively Pursuing Novel and Innovative Therapies
• 6.4 Novartis
  • 6.4.1 Novartis Acquisition of Chiron: A Major Biopharmaceutical Investment
  • 6.4.2 Protein Kinase Inhibitors
  • 6.4.3 Next Generation Oral Topoisomerase Inhibitor and Telomerase Promotors
  • 6.4.4 Novartis Sells of World-Wide Rights
  • 6.4.5 Biomarker and Proteomics Research
• 6.5 Sanofi-Aventis
  • 6.5.1 Target Screening and Validation
  • 6.5.2 Biologicals
  • 6.5.3 A Short Cut to Success?
  • 6.5.4 Aventis Divests Interest
  • 6.5.5 Recombine My Molecule

7 Competitive R&D Comparison on Oncology Drug Target Level

• 7.1 Target Overview
• 7.2 Head to Head Target Comparison by Molecular Function and Cancer Type
  • 7.2.1 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
  • 7.2.2 Receptor Activity Targets
  • 7.2.3 G-protein Coupled Receptor Activity Targets
  • 7.2.4 Protein Serine/Threonine Kinase Activity Targets
  • 7.2.5 Transcription Factor Activity Targets
  • 7.2.6 Transmembrane Receptor Activity Targets
  • 7.2.7 Catalytic Activity Targets
  • 7.2.8 Cytokine Activity Targets
  • 7.2.9 Protein-Tyrosine Kinase Activity Targets
  • 7.2.10 Kinase Activity Targets
  • 7.2.11 DNA Topoisomerase Activity Targets
  • 7.2.12 Growth Factor Activity Targets
  • 7.2.13 Ligase Activity Targets
  • 7.2.14 Motor Activity Targets
  • 7.2.15 Structural Constituent of Cytoskeleton Targets
  • 7.2.16 Transporter Activity Targets
  • 7.2.17 Targets According to Miscellaneous Molecular Function Groups
  • 7.2.18 Unclassified or Unknown Molecular Function of Targets
• 7.3 Drug Targets by Target Localization and Compound Type
• 7.4 Targets, Drugs and Cancer Indications Linked to Signaling Pathways
  • 7.4.1 Alpha6 Beta4 Integrin Signaling Pathway
  • 7.4.2 Androgen Receptor Signaling Pathway
  • 7.4.3 B Cell Receptor Signaling Pathway
  • 7.4.4 EGFR1 Signaling Pathway
  • 7.4.5 Hedgehog Signaling Pathway
  • 7.4.6 ID Signaling Pathway
  • 7.4.7 IL-1 Signaling Pathway
  • 7.4.8 IL-2 Signaling Pathway
  • 7.4.9 IL-3 Signaling Pathway
  • 7.4.10 IL-4 Signaling Pathway
  • 7.4.11 IL-5 Signaling Pathway
  • 7.4.12 IL-6 Signaling Pathway
  • 7.4.13 IL-9 Signaling Pathway
  • 7.4.14 Kit Receptor Signaling Pathway
  • 7.4.15 Notch Signaling Pathway
  • 7.4.16 T Cell Receptor Signaling Pathway
  • 7.4.17 TGF-beta Receptor Signaling Pathway
  • 7.4.18 TNF-alpha Signaling Pathway
  • 7.4.19 Wnt Signaling Pathway

8 Drug Compound Type Analysis

• 8.1 Deployment of Biological Based Compounds by Cancer Indications
• 8.2 Deployment of Chemical Based Compounds by Cancer Indications
• 8.3 Deployment of Natural Product Compounds by Cancer Indications

9 Drug Development in Oncology by Major Targeted Therapy Areas

• 9.1 Angiogenesis
• 9.2 Antibodies
• 9.3 Apoptosis
• 9.4 Protein Kinase Inhibitors
• 9.5 Vaccines

10 Cancer Indication Focus Analysis

• 10.1 Preclinical Stage Pipeline
• 10.2 Phase I Clinical Stage Pipeline
• 10.3 Phase II Clinical Stage Pipeline
• 10.4 Phase III Clinical Stage Pipeline
• 10.5 Drugs Soon to be on the Market
• 10.6 Approved Drugs

11 Disclaimer

12 Drug Index

13 Company Index

4.1 List of Tables

• Table 1: How to Navigate the Report
• Table 2: Number of Pursued Oncology Drugs Targets by Company
• Table 3: Pursued Oncology Drugs Targets by Molecular Function
• Table 4: Drug Target Expression Profiles in Humans
• Table 5: Identified Targets By Cancer Indications
• Table 6: Head to Head Comparison of Drugs with Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
• Table 7: Head to Head Comparison of Drugs with Receptor Activity Targets
• Table 8: Head to Head Comparison of Drugs with G-protein Coupled Receptor Activity
• Table 9: Head to Head Comparison of Drugs with Protein Serine/Threonine Kinase Activity
• Table 10: Head to Head Comparison of Drugs with Transcription Factor Activity Targets
• Table 11: Head to Head Comparison of Drugs with Transmembrane Receptor Activity Targets
• Table 12: Head to Head Comparison of Drugs with Catalytic Activity Targets
• Table 13: Head to Head Comparison of Drugs with Cytokine Activity Targets
• Table 14: Head to Head Comparison of Drugs with Protein-Tyrosine Kinase Activity Targets
• Table 15: Head to Head Comparison of Drugs with Kinase Activity Targets
• Table 16: Head to Head Comparison of Drugs with DNA Topoisomerase Activity Targets
• Table 17: Head to Head Comparison of Drugs with Growth Factor Activity Targets
• Table 18: Head to Head Comparison of Drugs with Ligase Activity Targets
• Table 19: Head to Head Comparison of Drugs with Motor Activity Targets
• Table 20: Head to Head Comparison of Drugs with Structural Constituent of Cytoskeleton Targets
• Table 21: Head to Head Comparison of Drugs with Transporter Activity Targets
• Table 22: Head to Head Comparison of Drugs with Targets According to Miscellaneous Molecular Function Groups
• Table 23: Head to Head Comparison of Drugs with Unclassified or Unknown Molecular Function Targets
• Table 24: Drug Target Comparison by Target Localization and Compound Type
• Table 25: Targeting Signaling Pathways: An Overview
• Table 26: Targeted Signaling Pathway Profiles of Big Pharma
• Table 27: Targets, Drugs and Cancer Indications Linked to the Alpha6 Beta4 Integrin Signaling Pathway
• Table 28: Targets, Drugs and Cancer Indications Linked to the Androgen Receptor Signaling Pathway
• Table 29: Targets, Drugs and Cancer Indications Linked to the B Cell Receptor Signaling Pathway
• Table 30: Targets, Drugs and Cancer Indications Linked to the EGFR1 Signaling Pathway
• Table 31: Targets, Drugs and Cancer Indications Linked to the Hedgehog Signaling Pathway
• Table 32: Targets, Drugs and Cancer Indications Linked to the ID Signaling Pathway
• Table 33: Targets, Drugs and Cancer Indications Linked to the IL-1 Signaling Pathway
• Table 34: Targets, Drugs and Cancer Indications Linked to the IL-3 Signaling Pathway
• Table 35: Targets, Drugs and Cancer Indications Linked to the IL-4 Signaling Pathway
• Table 36: Targets, Drugs and Cancer Indications Linked to the IL-5 Signaling Pathway
• Table 37: Targets, Drugs and Cancer Indications Linked to the IL-6 Signaling Pathway
• Table 38: Targets, Drugs and Cancer Indications Linked to the Kit Receptor Signaling Pathway
• Table 39: Targets, Drugs and Cancer Indications Linked to the Notch Signaling Pathway
• Table 40: Targets, Drugs and Cancer Indications Linked to the T Cell Receptor Signaling Pathway
• Table 41: Targets, Drugs and Cancer Indications Linked to the TGF-beta Receptor Signaling Pathway
• Table 42: Targets, Drugs and Cancer Indications Linked to the TNF-alpha Signaling Pathway
• Table 43: Targets, Drugs and Cancer Indications Linked to the Wnt Signaling Pathway
• Table 44: Deployment of Biological Based Compounds by Cancer Indications
• Table 45: Deployment of Chemical Based Compounds by Cancer Indications
• Table 46: Deployment of Natural Product Based Compounds by Cancer Indications
• Table 47: Comparative Presentation of Targeted Therapy Areas in Oncology
• Table 48: The Angiogenesis Pipeline by Cancer Type and Developmental Stage
• Table 49: The Antibody Pipeline by Cancer Type and Developmental Stage
• Table 50: The Apoptosis Pipeline by Cancer Type and Developmental Stage
• Table 51: The Protein Kinase Inhibitor Pipeline by Cancer Type and Developmental Stage
• Table 52: The Cancer Vaccine Pipeline by Cancer Type and Developmental Stage
• Table 53: Summary of Big Pharma' s Preclinical Stage Pipeline
• Table 54: Preclinical Stage Pipeline by Cancer Indications
• Table 55: Summary of Big Pharma' s Phase I Clinical Stage Pipeline
• Table 56: : Phase I Clinical Stage Pipeline by Cancer Indications
• Table 57: Summary of Big Pharma' s Phase II Clinical Stage Pipeline
• Table 58: Phase II Clinical Stage Pipeline by Cancer Indications
• Table 59: Summary of Big Pharma' s Phase III Clinical Stage Pipeline
• Table 60: Phase III Clinical Stage Pipeline by Cancer Indications
• Table 61: Oncology Drugs Soon to be on the Market
• Table 62: Summary of Big Pharma' s Approved Oncology Drugs
• Table 63: Approved Drugs by Cancer Indications